Abstract 5801
Background
Malignant tumors represent a major public health problem in the world and Mexico is not the exception. The development of Population-Based Cancer Registries (PBCR) that collect cancer cases in a determined locality and help evaluate health programs is fundamental. In Mexico there were only a couple of attempts on hospital and histopathological registries, reason why it was decided to implement a PBCR, named as the National Network of Cancer Registries (NNCR).
Methods
During the creation process, support was received from the International Agency of Research in Cancer (IARC), through the Global Initiative for Cancer Registry Development. The NNRC is operated in a central level located in Mexico City, and the cases in the sources of information established are registered in a national registration form composed of 29 variables structured and standardized according to international guidelines. The collection and administration of information is done through a technological system, called RedCancerMX in a mobile and web application hosted on the cloud.
Results
In 2016, the General Health Law was modified to create the National Cancer Registry and in 2017 it was approved. In July 2018 the regulations of the NNCR are published, which establishes the bases for organization, integration and coordination. To the date, the NNCR is active in 8 cities, reaching 10% of national coverage. The process of integration of each city to the NNCR, included a feasibility analysis, validation and training. The process of obtaining data covers subprocesses of collection, validation and authorization carried out by medical specialists. RedCancerMX had integrated 11 validations established by international organizations to guarantee the quality of the information and they are aligned to quality indicators proposed by the IARC: comparability, validity, timeliness and completeness.
Conclusions
In Mexico, the NNCR is already established, which is considered an epidemiological surveillance system with national, active and continuous validity. This NNCR will allow us to determine the incidence of cancer and survival rates in the Mexican population, helping to implement new and better strategies for cancer control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Nacional de Cancerología.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract